📊 BYSI Key Takeaways
Is BeyondSpring Inc. (BYSI) a Good Investment?
BeyondSpring is a pre-revenue pharmaceutical company with negative stockholders equity of -$34.5M, indicating technical insolvency on a book value basis. With only $4.0M cash against annual operating burn of -$3.3M, the company faces critical liquidity constraints and approximately 12-16 months of runway absent capital infusion or commercialization breakthrough.
BeyondSpring's fundamentals are very weak: it has no revenue, negative operating cash flow, and materially negative stockholders' equity. The reported net income appears inconsistent with the operating loss and likely reflects non-core or one-time items rather than durable earnings power, so growth quality and financial health remain poor.
BeyondSpring Inc. Key Strengths (BYSI)
- Modest cash position of $4.0M provides near-term operational buffer
- Pharmaceutical sector with implied clinical pipeline in development
- Recent insider activity (7 Form 4 filings) suggests management engagement
- Cash balance of $12.48M provides some near-term operating flexibility
- Current and quick ratios of 1.89x indicate acceptable short-term liquidity relative to current liabilities
- Net loss metrics showed some year-over-year improvement at the bottom line
BYSI Stock Risks: BeyondSpring Inc. Investment Risks
- Negative stockholders equity of -$34.5M indicates balance sheet insolvency and structural financial distress
- Zero revenue generation with no FDA-approved products; entirely pre-commercial stage with execution risk
- Operating cash burn of -$3.3M annually against limited cash creates severe funding urgency within 12-16 months
- Liabilities of $48.8M exceed assets by $30.4M; limited debt servicing capacity without dilutive capital raises
- Current ratio of 1.09x indicates tight liquidity with minimal margin for adverse developments
- Zero revenue means the business has not demonstrated commercial viability
- Free cash flow of -$14.31M and operating cash flow of -$14.27M indicate continued cash burn
- Negative stockholders' equity of -$31.77M signals a highly stressed balance sheet and limited financial flexibility
Key Metrics to Watch
- Cash balance depletion rate and remaining runway to next funding event
- Clinical trial progression and FDA regulatory milestones toward revenue-generating approvals
- Quarterly operating cash burn trends and burn rate acceleration indicators
- Capital raise activity and dilution impact on existing shareholders
- Quarterly operating cash burn relative to cash on hand
- Any sustained revenue generation and improvement in stockholders' equity
BeyondSpring Inc. (BYSI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
BeyondSpring Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BYSI Profit Margin, ROE & Profitability Analysis
BYSI vs Healthcare Sector: How BeyondSpring Inc. Compares
How BeyondSpring Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BeyondSpring Inc. Stock Overvalued? BYSI Valuation Analysis 2026
Based on fundamental analysis, BeyondSpring Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BeyondSpring Inc. Balance Sheet: BYSI Debt, Cash & Liquidity
BYSI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BeyondSpring Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.28 indicates the company is currently unprofitable.
BYSI Revenue Growth, EPS Growth & YoY Performance
BYSI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$2.2M | N/A |
| Q3 2025 | N/A | $1.1M | $-0.03 |
| Q2 2025 | N/A | -$1.8M | $-0.04 |
| Q1 2025 | N/A | -$3.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BeyondSpring Inc. Dividends, Buybacks & Capital Allocation
BYSI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BeyondSpring Inc. (CIK: 0001677940)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BYSI
What is the AI rating for BYSI?
BeyondSpring Inc. (BYSI) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BYSI's key strengths?
Claude: Modest cash position of $4.0M provides near-term operational buffer. Pharmaceutical sector with implied clinical pipeline in development. ChatGPT: Cash balance of $12.48M provides some near-term operating flexibility. Current and quick ratios of 1.89x indicate acceptable short-term liquidity relative to current liabilities.
What are the risks of investing in BYSI?
Claude: Negative stockholders equity of -$34.5M indicates balance sheet insolvency and structural financial distress. Zero revenue generation with no FDA-approved products; entirely pre-commercial stage with execution risk. ChatGPT: Zero revenue means the business has not demonstrated commercial viability. Free cash flow of -$14.31M and operating cash flow of -$14.27M indicate continued cash burn.
What is BYSI's revenue and growth?
BeyondSpring Inc. reported revenue of $0.0.
Does BYSI pay dividends?
BeyondSpring Inc. does not currently pay dividends.
Where can I find BYSI SEC filings?
Official SEC filings for BeyondSpring Inc. (CIK: 0001677940) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BYSI's EPS?
BeyondSpring Inc. has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BYSI's fundamental grade?
Based on our AI fundamental analysis in June 2026, BeyondSpring Inc. has a D grade with 94% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BYSI stock overvalued or undervalued?
Valuation metrics for BYSI: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BYSI's AI grade for 2026?
Our dual AI analysis gives BeyondSpring Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BYSI's free cash flow?
BeyondSpring Inc.'s operating cash flow is $-3.3M, with capital expenditures of $0.0.
How does BYSI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 1.09 (avg: 2).